Tailored treatment to patients with metastatic colorectal cancer
Pfeiffer, P.; Qvortrup, C.; Hansen, T.P.
Ugeskrift for Laeger 171(13): 1098
2009
ISSN/ISBN: 1603-6824 PMID: 19321093 Document Number: 628575
Document emailed within 1 workday
Related Documents
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954Halámková, J.; Tomášek, J.; Rybníčková, S.; Adámková Krákorová, D.; Bencsiková, B.; Kiss, I. 2013: The current approach to the treatment of the patients with metastatic colorectal cancer Vnitrni Lekarstvi 59(10): 903-908
Karacetin, D.; Yalcin, B.; Okten, B.; Ozturk, S.; Maral, O.; Incekara, O. 2009: Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 14(4): 605-608
Cokmert, S.; Demir, L.; Can, A.; Akyol, M.; Vedat Bayoglu, I.; Dirican, A.; Kucukzeybek, Y.; Erten, C.; Oktay Tarhan, M. 2014: Capecitabine-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 19(1): 75-82
Watanabe, T.; Sawada, T.; Kubota, Y.; Ooya, M.; Masaki, T.; Sameshima, S.; Shinozaki, M.; Tsuno, N.; Uchiyama, M.; Sakaguchi, M. 1992: Continuous intra-arterial infusion chemotherapy in colorectal cancer patients with nonresectable metastatic liver cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(10 Suppl): 1515-1518
Lee, J.J.; Sun, W. 2016: Options for Second-Line Treatment in Metastatic Colorectal Cancer Clinical Advances in Hematology and Oncology: H&o 14(1): 46-54
Pfeiffer, P.; Jensen, B.V. 2005: Drug therapy of patients with metastatic colorectal cancer Ugeskrift for Laeger 167(45): 4261-4265
Kamnerdsupaphon, P.; Lorvidhaya, V.; Chitapanarux, I.; Tonusin, A.; Sukthomya, V. 2007: FOLFIRI chemotherapy for metastatic colorectal cancer patients Journal of the Medical Association of Thailand 90(10): 2121-2127
Otani, Y.; Kondo, T.; Saito, R.; Matsumura, Y.; Ohura, H.; Hirose, M.; Horikoshi, A.; Sado, T.; Sugita, M.; Okaniwa, G. 1995: Surgical treatment of metastatic lung tumor from colorectal cancer Kyobu Geka. Japanese Journal of Thoracic Surgery 48(9): 735-740
Al-Hajeili, M.; Marshall, J.L.; Smaglo, B.G. 2016: Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer Oncology 30(1): 10-16
Sasaki, K.; Takasaka, H.; Nishikawa, N.; Yoshikawa, T.; Hirata, K. 2003: Home chemotherapy and outpatient treatment for metastatic colorectal cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 61(Suppl 7): 333-337
Kemeny, N.E. 2000: Hepatic arterial therapy for the treatment of metastatic colorectal cancer Seminars in Oncology 27(5 Suppl 10: 126-131
Suzuki, T.; Sakamoto, Y.; Morohashi, H.; Miura, T.; Sato, K.; Hakamada, K. 2018: Appropriateness of Regorafenib Administration to Patients with Metastatic Colorectal Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(13): 2012-2014
Vrdoljak, E.; Omrcen, T.; Boban, M.; Hrepic, D. 2008: Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients Journal of BUON: Official Journal of the Balkan Union of Oncology 13(4): 513-518
Iwasa, S.; Shimada, Y. 2011: Treatment strategy of chemotherapy for unresectable metastatic or recurrent colorectal cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 3): 427-432
Takiuchi, H. 2010: Current status and perspectives of biologics in the treatment of metastatic colorectal cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 68(10): 1866-1870
Grothey, A. 2015: Maintenance therapy in the treatment of metastatic colorectal cancer. Axel Grothey, MD Oncology 29(8): 560; 594
des Guetz, G.; Mariani, P.; Cucherousset, J.; Benamoun, M.; Lagorce, C.; Sastre, X.; Le Toumelin, P.; Uzzan, B.; Perret, G.Y.; Morere, J.F.; Breau, J.L.; Fagard, R.; Schischmanoff, P.O. 2007: Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer Anticancer Research 27(4c): 2715-2719
Burz, C.; Berindan-Neagoe, I.; Balacescu, O.; Todor, N.; Pelau, D.; Floares, C.; Kacso, G.; Tanaselia, C.; Ursu, M.; Vlase, L.; Leucuta, S.E.; Cristea, V.; Irimie, A. 2010: Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters Journal of BUON: Official Journal of the Balkan Union of Oncology 15(2): 263-269
Hibi, K.; Mizukami, H.; Saito, M.; Kigawa, G.; Nemoto, H. 2014: P16 Methylation is frequently detected in the serum of metastatic colorectal cancer patients Hepato-Gastroenterology 61(130): 354-356